Correspondence 0001193125-22-309125 from Syros Pharmaceuticals, Inc. (SYRS) (CIK 0001556263)
Syros Pharmaceuticals, Inc. (SYRS) (CIK 0001556263)
Date: Dec. 20, 2022 · CIK: 0001556263 · Accession: 0001193125-22-309125
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-267888
Letter
December 20, 2022
VIA EDGAR SUBMISSION
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Attention: Lauren Hamill
Tim Buchmiller
Re: Syros Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-267888
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Syros Pharmaceuticals, Inc. hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-267888), so that it may become effective at 4:00 p.m., Eastern Time, on December 22, 2022, or as soon as practicable thereafter.
Very truly yours,
SYROS PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP December 20, 2022 VIA EDGAR SUBMISSION Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Lauren Hamill Tim Buchmiller Re: Syros Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-267888 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Syros Pharmaceuticals, Inc. hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-267888), so that it may become effective at 4:00 p.m., Eastern Time, on December 22, 2022, or as soon as practicable thereafter. Very truly yours, SYROS PHARMACEUTICALS, INC. By: /s/ Gerald E. Quirk Name: Gerald E. Quirk Title: Chief Legal Officer